Concourse Financial Group Securities’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-98
Closed -$1.42K 1347
2024
Q4
$1.42K Hold
98
﹤0.01% 2054
2024
Q3
$1.45K Hold
98
﹤0.01% 2026
2024
Q2
$1.36K Hold
98
﹤0.01% 2087
2024
Q1
$1.54K Hold
98
﹤0.01% 2083
2023
Q4
$1.58K Hold
98
﹤0.01% 2052
2023
Q3
$1.21K Hold
98
﹤0.01% 2080
2023
Q2
$1.57K Hold
98
﹤0.01% 2056
2023
Q1
$1.71K Hold
98
﹤0.01% 2085
2022
Q4
$905 Hold
98
﹤0.01% 2183
2022
Q3
$1K Sell
98
-50
-34% -$497 ﹤0.01% 1904
2022
Q2
$1K Hold
148
﹤0.01% 2120
2022
Q1
$2K Sell
148
-341
-70% -$7.18K ﹤0.01% 2036
2021
Q4
$17K Hold
489
﹤0.01% 1701
2021
Q3
$24K Sell
489
-550
-53% -$25.5K ﹤0.01% 1603
2021
Q2
$47K Sell
1,039
-50
-5% -$2.21K ﹤0.01% 1339
2021
Q1
$53K Buy
1,089
+627
+136% +$32.6K ﹤0.01% 1204
2020
Q4
$25K Sell
462
-50
-10% -$2.26K ﹤0.01% 1388
2020
Q3
$19K Sell
512
-200
-28% -$7.43K ﹤0.01% 1380
2020
Q2
$22K Buy
712
+24
+3% +$665 ﹤0.01% 1270
2020
Q1
$19K Buy
+688
New +$20.6K ﹤0.01% 1256

Other funds holding NEO

Concourse Financial Group Securities's NEO Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of NeoGenomics (NEO) in Q1 2025, closing a stake of 98 shares — an estimated $1.42K sold.

Concourse Financial Group Securities first reported a position in NEO in Q1 2020 and held it in 20 quarters. The position peaked at $53K in Q1 2021. 256 funds tracked by Wall St. Rank hold NEO as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining NeoGenomics position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 98 NeoGenomics shares in Q1 2025, an estimated $1.42K.
  • Concourse Financial Group Securities first reported a position in NeoGenomics in Q1 2020 and held it in 20 quarters.
  • Concourse Financial Group Securities's NeoGenomics position peaked at $53K in Q1 2021.
  • 256 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.